The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

Those results were sufficient for the trial to meet its primary endpoints, Novo Nordisk said in a Friday release. Digging deeper into the data, 37% of patients treated with semaglutide achieved ...

In the trial, semaglutide 2.4 mg appeared to have a ... executive vice president and head of Development at Novo Nordisk. “Among people with overweight or obesity, one in three live with MASH.

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

Amid shortages and rising demand for branded drugs, compounded semaglutide has gained popularity due to its affordability. However, Novo Nordisk contends that only FDA-approved versions should be ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that the ...